Fig. 5

miRNA agomirs rescue memory deficits in APP/PS1 mice. a, b Rescue of behavioral deficits of 10–11-MO APP/PS1 mice treated with m10- or m37-agomir 4 weeks after icv injection (a) or 2 weeks after completion of the 30-day intranasal treatment (b) in the spatial acquisition of MWM test. Latency to reach the platform in the acquisition phase, swimming speed, escape latency to reach the original platform location, time in platform area and number of crossings during the probe trial are presented. Data are presented as mean ± SEM, n = 7–11 mice each group. c Rescue of behavioral deficit of 10-MO APP/PS1 mice treated with m10- or m37-agomir 1 week after completion of the 30-day intranasal treatment in Barnes maze. Latency, speed, time in the target area and target hole during the learning phase and the probe trial are presented. Data are presented as mean ± SEM, n = 11 mice each group. For (a–c), data were analyzed with one-way ANOVA